Introduction
Clinical management of spinal cord injury (SCI) has significantly improved its general prognosis. However, to date, traumatic paraplegia and tetraplegia remain incurable, despite massive research efforts.
Incidence and prevalence
In 1995, Blumer and Cline estimated the incidence and prevalence of SCI to be between 13 and 33 cases per million per year, and from 110 to 1120 per million population, respectively [1] . On this basis, Wyndaele and Wyndaele reviewed the more recent literature in 2006 and found that, despite considerable variations among study methods and reporting, incidence and prevalence do not seem to have changed substantially over recent years. In their review, the incidence and prevalence ranges are of 10.4 and 83 per million inhabitants per year and 223-755 per million inhabitants, respectively [2] . These data may not be sufficiently representative for a worldwide estimate, but, at the least, give an idea of the magnitude of the problem.
Individual and socio-economical impact
Traumatic SCI is a catastrophe for the individual concerned. Para-and tetraplegia deprive their victims of locomotion, sphincter and sexual function, their autonomy, private and professional perspectives, as well as working capacity. Many previously basic routines become challenging obstacles and patients are exposed to specific medical complications [3] (see below). After 35 years of follow-up in the National SCI database (since 1973), the main causes of death are pneumonia, septicaemia, and pulmonary embolism [4] . Nevertheless, with present clinical management, life expectancy of spinal cord injured patients approaches the population average in developed countries, though without reaching normal values.
The socio-economical impact of SCI remains considerable. Approximately 80% of patients are young males, with an average age at injury of less than 40 years. About half of patients suffer from tetraplegia, the other half from paraplegia. More than half of the patients reported being employed before the injury. By 20 and 30 years after injury, slightly more than a third are employed again (less tetraplegics than paraplegics) [4, 5] . Lifetime costs in the United States have been estimated to range from approximately 500,000 US$ for a 50 year old incompletely injured patient to more than 3,000,000 US$ for a 25 year old completely tetraplegic patient. This does not include indirect costs of >65,000 US$ per year, accounting for loss of wages, fringe benefits and productivity [4] .
Over the last decades, governments and non-medical, non-governmental associations and foundations have increasingly participated in the attempts to reduce the incidence and gravity of traumatic injuries, including brain and spinal cord injuries. One example is the Think First foundation (www.thinkfirst.org=) that raises awareness of the gravity of these injuries and their potential prevention via educational campaigns and advertising, specifically targeting children and young adults, as well as motor vehicle users. The widespread introduction of safety measures like the legal requirements for seat belts and helmets, the reduction of speed limits on roads, and more, appear to reduce the incidence of head and spine trauma [6] [7] [8] [9] [10] [11] [12] .
Neurobiology of SCI

Spinal cord syndromes
Paraplegia and tetraplegia due to SCI result from the interruption of the connections between the supra-spinal control centres and the spinal cord circuits caudal to the lesion site, i.e., the deafferentation of the sub-lesional cord. This deafferentation occurs to a variable degree, depending on the extent of the lesion. Therefore, the so-called ''spinal cord syndromes'' may be incomplete or complete. In incomplete cord syndromes (approx. 50% of the cases), the loss of sensory and=or motor function below the level of injury is partial, and the type of neurologic deficit is variable. In complete cord syndromes (the remaining 50%), motor and sensory function below the level of the lesion is entirely lost.
So-called discomplete spinal cord syndromes are clinically complete, but neurophysiologically incomplete. Thus, even in clinically complete SCI, there is residual brain influence on spinal cord function below the lesion [13] . In one study, more than four out of five clinically complete syndromes could be neurophysiologically classified as discomplete [14] , and, thus, in many patients, there may be central nervous circuitry above the spinal cord lesion that could potentially be recruited to influence the evolution of even clinically complete spinal cord syndromes.
The spinal cord lesion
Evolution of the lesion after the initial trauma Displacement of the elements of the spine results in compression, shearing, laceration and other immediate mechanical damage of the spinal cord and associated structures, such as blood vessels and meninges. This is the primary injury, which can be worsened at the time of the accident by hypotension, due to spinal shock and hypoxia. Within the cord, a complex, auto-destructive cascade of secondary events is initiated, leading to hypoxia, ischemia and free radical production, ion imbalances, excitotoxicity and programmed cell death, protease activation, and inflammation including eicosanoid=prostaglandin pro- duction. Local extension of the damage thus further disrupts the three-dimensional organisation of the cord [14] [15] [16] [17] .
Over a time period of days to weeks post-injury, progressive cell death occurs, the three-dimensional organisation of the spinal cord architecture continues to degenerate, and the necrotic lesion spreads, damaging increasingly more axons in the white matter tracts [18] as well as neuronal cell bodies in the grey matter (especially in the cervical and lumbar enlargements), resulting in worsened neurological deficits. Although the impact of these secondary injury processes on parenchymal damage and loss of neurological function cannot be precisely quantified, the phase between the initial trauma and the constitution of the definitive cord lesion represents a therapeutic window of opportunity which has been the focus of a significant neuroprotective research effort [19] .
Histopathologicaly, experimental compressive spinal cord lesions in the rat initially show tissue oedema and petechial bleeding in the grey matter. Over time, the distal components of severed axons degenerate, neurons and oligodendrocytes undergo apoptosis, and an astroglial and connective scar tissue forms. Glial scarring occurs at the lesion site and surprisingly also in the degenerated fibre tracts (including the human corticospinal tract [20] ) at 1 year after injury. The spinal cord undergoes atrophic changes, and, in many cases, cyst formation can be observed (Fig. 1) .
Human spinal cord injury
Human spinal cord injury can be classified into four types [21, 22] : contusion, maceration, laceration, and solid cord injury.
The most common lesion is the contusion-type injury, associated with variable degrees of haemorrhage within parenchymal oedema (Fig. 2) . The more severe, still common maceration-type injury is due to massive compression of the cord, interrupting the cord's surface and resulting in complete sublesional paralysis. Disruption of the meninges activates a fibroblastic scarring response that may lead to tethering of the cord to the meninges. About one fifth of the lesions reported in the initial description of these types of injury were lacerations, due to penetrating wounds (or penetration of the cord by bone fragments), or, in children, to brutal stretching of the cord. All these lesions may evolve into a gliotic scar or one or several intramedullary cysts. When the cord surface is severed, the tethering of the cord may result in neurological deficits. Syringomyelia may also develop and must always be suspected when neurological deterioration occurs, especially in a previously neurologically stable patient.
''Solid cord injury'' corresponds to the pathological changes underlying the so-called acute traumatic central cord syndrome, which is typically due to compression of the cervical spinal cord during sudden hyperextension of an arthrotic cervical spine with a spinal canal narrowed by osteophytes and ligamentum clinical prognosis is much better than in the other types of spinal cord injury. In more recent studies, MRI has not shown haematoma but T2 hypersignal in the acute stage, and underlying pathological changes correspond to oedema and axonal swelling, not to haemorrhage ( Fig. 3 ) [23, 24] . In strict anatomical terms, human SCI is incomplete in most cases, and neurological recovery may be extensive, even when the lesion has damaged a significant portion of the spinal white matter [25] . Equivalent phenomena to the axonal degeneration observed in the experimental setting can be observed in humans (Fig. 4) [26, 27] .
Axonal regeneration
Since the clinically important neurological deficits after SCI result from the loss of nerve fibres in white matter tracts, i.e., the axonal connections of the supralesional centres to the sub-lesional cord, axonal regeneration offers a promising therapeutic perspective for ''rewiring'' the spinal cord.
However, it was long thought to be impossible. In his classic treatise on nervous system degeneration and regeneration, Ramon y Cajal argued that ''Once development was ended, the founts of growth and regeneration of the axons and dendrites dried up irrevocably. In the adult centres, the nerve paths are something fixed, ended and immutable. Everything must die, nothing may be regenerated. It is for the science of the future to change, if possible, this harsh decree'' [28] .
Nonetheless, already a hundred years ago, Cajal's student J. F. Tello had grafted peripheral nerve segments onto CNS tissue and shown that central nervous system neurons could regenerate into that environment [29] . At the beginning of the 1980s, the group of Aguayo published descriptions of the growth potential of CNS axons into peripheral nerve [30] and found that these CNS axons were basically functional, although with limited or altered synaptic contacts (probably due to the absence of their target) [31] . During the same period, donor fetal CNS neurons were shown to integrate into lesioned spinal cord tissue and even to ''rescue'' injured supraspinal neurons in the neonatal brainstem [32] [33] [34] . In the lesioned adult rat spinal cord, a substantial intrinsic axonal regenerative attempt was demonstrated (Fig. 5) , although it showed signs of spontaneous regression after a few weeks [35] .
Since the experimental demonstration that CNS neurons do have the potential to regenerate, research has focussed on the factors that influence CNS axonal regeneration [36] , in particular the axon-growth inhibitory glial scar [37] (first described by Cajal [28] ). Two environmental factors have been identified that are widely acknowledged to play major roles in preventing axon regeneration and plasticity in the injured adult mammalian brain and spinal cord: CNS myelin-associated molecules [38, 39] and the family of highly sulphated chondoitin sulphate proteoglycans (CSPGs [40] ).
Traumatic injury causes the release, as debris, of several myelin associated axon growth inhibitory molecules, the most potent of which is the gylcoprotein NOGO-A. It induces the rapid, Nogo-receptor (NgR)-mediated collapse of axonal growth cones by the activation of the small GTP-ase RhoA (e.g. [41] ). The potent axon growth inhibitory effects of the myelin associated molecules at the lesion site is supported by the rapid expression of the axon-repulsive, highly sulphated proteoglycans in-and around the lesion site [42] .
In addition, complex inflammatory processes occur after acute SCI, and they represent a ''dual-edged sword''. Microglia-derived and blood-borne derived macrophages are integral components of this inflammatory response in- and around the lesion site. The phenotype and activation status of these cells have been reported to have profound effects on their ability to enhance the secondary degenerative events or to promote CNS axon regeneration and tissue repair [43, 44] . Various cytokines influence the evolution of the secondary injury cascade in a sometimes detrimental, sometimes favourable manner. The macrophage response to SCI is complex, but modulation of their activity may have the potential to enhance recovery (possibly, among other roles, by clearing growth inhibitory myelin debris from the lesion site [45, 46] ), and many experimental treatments interact with these macrophages [47] .
The sub-lesional segment
The spinal cord, as part of the CNS, is more than a passive conduit and relay for neural messages between the supraspinal centres and the peripheral nerves. A complex intrinsic circuitry exists, mainly in the cervical and lumbar enlargements of the spinal cord. These circuits autonomously generate structured neural activity, including rhythmic output, which results in basic locomotor patterns [48, 49] . After cervical or thoracic SCI, the lumbar circuitry remains anatomically intact, and plastic alterations (see below) appear to be responsible for change in neurological presentation that can be observed over time.
Influence of spinal cord white matter on neurological recovery
Although the neurological deficits are for the most part irreversible, the clinical presentation may thus evolve over time. Spasticity develops, bladder function changes, and patients may progressively recover some of their lost sensory or motor function. The spinal cord's white matter tracts, even when they are partially damaged, play an important role in functional recovery after SCI, and there is evidence in humans that white matter tracts influence spinal cord plasticity [50] . In the experimental setting, white matter tract preservation directly mediates recovery after SCI [51] . After complete transection of the cord, there is usually no significant locomotor recovery, but very limited white matter sparing at the lesion site is sufficient to influence the functional reorganisation of the sub-lesional cord [52, 53] . Very small increases in spared tissue at the centre of the lesion have profound effects on basic locomotor recovery, and sparing of 5-10% of the fibres in the white matter tracts is sufficient to help drive circuits involved locomotion [53, 54] .
Fundamental therapeutic approaches
Three types of potential treatment strategies for SCI result from the above: neuroprotection, repair of the lesion site and recruitment of the preserved nervous system (enhancing plasticity).
Neuroprotection
Neuroprotective treatments are designed to interfere with the cascade of events that lead to secondary tissue injury in order to decrease the progressive extension of the lesion and damage to the spinal cord parenchyma, in particular the white matter tracts. Some degree of preservation of the connections between the supraspinal centres and the sub-lesional cord would lead to lessened neurological deficits. However, although neuroprotective strategies were designed for potentially rapid clinical application and have been intensively investigated (see below), the ''magic bullet'' has yet to be found (for detailed recent reviews, see [55, 56] ).
Repair of the lesion site
Once the lesion has been established and the sub-lesional cord deafferented, the ideal therapeutic approach would be the repair of the lesion with the appropriate reconnection or synaptic re-establishment being accomplished by regrowing axons. Axonal regeneration is, however, only a first step in the complex sequence which could potentially lead to useful spinal cord repair: after nerve fibre regrowth into the lesion site through a fibroglial scar, an axon would have to grow in an orientated manner over a sufficient distance of lesion tissue to cross the entire lesion site. It would then be required to exit the lesion site and continue its growth in the sub-lesional central nervous parenchyma, where it would have to reach an appropriate target, stop its growth and form synaptic contacts with remaining, intact neuronal circuits. Many of the regenerating axons would also require myelination, to finally re-establish impulse conduction and the reformation of a viable, functional circuitry. This sets an ambitious goal. Achieving it will depend on the combination of a number of different strategies addressing these obstacles:
Removal or blockade of the major axon growth inhibitory influences in the environment of the injured CNS. Antibodies against NOGO-A (see above) have been demonstrated to enhance axonal regeneration from lesioned fibres and to increase compensatory nerve fibre sprouting from non lesioned fibres in numerous animal models. This has been associated with improved functional outcome (e.g., [57, 58] ). Also, the infusion of the enzyme chondroitinase ABC into damaged CNS tissues results in the digestion of the inhibitory sulphated glycosaminoglycan side-chains of the CSPGs and promotes enhanced axon regeneration and plasticity of long-distance projecting sensory axons as well as the return of some degree of motor and sensory function [59] . Stimulate axonal regeneration and enhance plasticity. Since the fate of severed-and spared axons within the lesioned CNS depends on the balance between axon growth-promoting factors and axon growth-inhibitory factors, enormous effort has been expended in devising strategies that tip the balance in favour of axon regeneration and enhanced plasticity. Strategies include the direct infusion of neurotrophic growth factors or their local production by genetically engineered donor cells [60] , and the implantation of axon growth-promoting cells (e.g. Schwann cells, olfactory nerve ensheathing cells and bone marrow derived stromal cells) that intrinsically express a range of molecules extracellular matrix molecules, cell surface adhesion molecules and growth factors known to support nerve fibre growth [61] . Provision of an orientated 3D structure to guide growth polymer scaffolds. A number of guidance structures or scaffolds of increasingly sophisticated design have been investigated for this purpose. Such designs range from the use of simple hollow conduits to more complex devices with microstructures intended to reproduce the general architecture of spinal cord grey-and white matter. Both synthetic and natural polymers have investigated for such devices but the ideal scaffold with optimal functionalisation (e.g. in combination with axon growth promoting cells) has yet to be determined (for a recent review, see [62] ). Part of the impetus for such strategies aiming to reconnect severed nerve fibres to their original targets has come from the fact that only a small percentage (1-10%) of the original nerve fibre projection is needed for the maintenance of useful motor or sensory function [63, 64] .
Currently, the measurable functional improvement after experimental repair remains moderate at best [65] . Nonetheless, an impressive number of repair strategies have already found their way into clinical trials (see below).
Recruiting preserved tissue
The third therapeutic access is the recruitment of remaining, preserved nervous tissue, including the remaining intrinsic circuitry of the spinal cord. This includes enhanced plasticity of the sub-lesional locomotor circuits and the long white matter tracts that control these circuits. The goal is to modulate neuronal activity in order to increase neurological recovery, while avoiding undesirable effects such as excessive spasticity.
The locomotor system
The locomotor activity in the lower limbs of mammals is based on the finely tuned interaction of a tripartite system. The three components are:
(1) The basic, rhythmic neuronal activity of a cellular network located in the lumbar spinal cord called the locomotor ''central pattern generator'' (CPG). This neural network can be found in the spinal cord of all vertebrates, like the lamprey [66] and mammals [48] including humans [49, 67, 68] . The locomotor CPG may produce coordinated motor patterns in isolation. In the human newborn (before the maturation and myelination of the corticospinal tract which controls voluntary movement), and even in anencephalic children, stepping movements can be observed, both in the absence of peripheral stimuli, or in response to the latter [69] . (2) Supraspinal input modulating the locomotor activity of the CPG. This results in the supraspinal activation of rhythmic walking, ipsilateral coordination of flexors and extensors, and left-right coordination. (3) Sensory feedback from the lower limbs, reaching the CPG through peripheral nerves. This creates dynamic sensorimotor interactions, either directly with the CPG, or, via ascending and descending long white matter tracts, after processing by supraspinal motor centres [70] , modulating the rhythmic activity of the CPG to adapt to complex external requirements. For example, when needed, voluntary commands and subconscious control mecanisms maintain balanced locomotion even when exterior constraints change, for example during walking on uneven ground.
Most human spinal cord injuries are located in the thoracic or cervical cord. Thus, the CPG is generally caudal to the lesion and not directly injured itself. Anatomically intact, it is deafferented through interruption of the white matter tracts and loss of supraspinal control. Therefore, functional locomotor output may be recovered if the interplay between supraspinal control, persisting peripheral input, and the CPG could be reconstructed. This depends on CNS plasticity.
Spinal cord plasticity
The spinal cord's circuitry is capable of plasticity throughout life and neuronal circuits within the human spinal cord also appear to be capable of a certain degree of ''learning'' [71] [72] [73] . After SCI, spontaneous motor recovery, development of spasticity, central neuropathic pain, autonomic dysreflexia, and emergence of bladder and sphincter dyssynergy after initial areflexia (all relying on lumbar spinal cord circuitry) result from plastic changes in the deafferented cord. This plasticity can be exploited. The spinal cord can learn to perform a task that it practices and exercise can modulate plasticity [74] and enhance the expression of growth factors in the central nervous system [74] , suggesting a link between exercise, the expression of neurotrophins such as BDNF and NT-3, as well as possible functional recovery [74] [75] [76] [77] . Treadmill locomotor training has been investigated in the experimental setting [78] and in human neurorehabilitation. In addition, pharmacological studies have investigated the possibility of increasing functional recovery by restoring the disturbed neuro-chemical environment in the preserved spinal cord in order to influence the caudal cord circuitry [79] .
Current clinical treatment
Acute management
On the one hand, any victim of significant trauma must be considered to have a spinal injury until the opposite can be ascertained by clinical or radiological assessment. Suspected spinal injuries and SCI may thus complicate management of trauma patients because they require specific manoeuvres.
In order to avoid secondary injury to the spinal cord from an injured and displaced spinal segment, trauma patients must be moved and transported in a secure and stable position, achieved by the placement of a rigid cervical collar, en bloc handling of the patient, and transport in the supine position on a backboard or a deflatable transport mattress. Airway management in trauma patients must take into consideration the possibility of a cervical spine injury. In addition, the immobilisation of the patient must still allow 90% rotation of the patients body to protect the airway in case of emesis. Perfusion pressure of the injured spinal cord must be maintained. Hypotension may be due to or worsened by neurogenic peripheral vasoplegia. The diagnosis of blood loss due to associated injuries is essential. Fluid resuscitation aims for a minimal systolic blood pressure of approximately 100 mmHg and an ideal heart rate of 80 beats per minute . Oxygen supplementation should be given not only for pulmonary complications, but also to maintain oxygenation in the injured cord.
On the other hand, associated injuries must be actively investigated and treated, especially intracranial lesions and occult bleeding. Immediately after the impact on the cord, neurological function is lost. After reversal of the initial ''spinal shock'' (i.e., an acute, reversible functional silencing of neurological spinal cord activity due to the impact), the remaining neurological deficit over the first few days is quite predictive of the final outcome. If the deficit is complete and remains so over the first days, recovery is highly unlikely. Incomplete injuries have more favourable prognosis and very significant recovery may be seen over the months that follow the initial injury.
Surgery
Once medically stabilised, those spinal injuries that are sufficiently severe to have resulted in spinal cord injury and neurological deficits should be surgically stabilised, although this approach is not formally supported by currently available evidence according to a recent Cochrane review [80] . For complete injuries, timing of surgery depends more on the surgeons conviction of the usefulness of spinal decompression in a neuroprotective perspective than on spinal stability. The latter must however be obtained in order to facilitate general care of the patient, e.g. positioning to avoid pulmonary complications, and early mobilisation for rehabilitation.
Chronic care
Ultimately, 90% of patients will return home and gain a certain degree of independence. Medical complications remain common, especially with more severe deficits and in older patients, and are responsible for a high rate of readmissions (55% in the first year, then more than a third of the patients per year). The most significant complications are due to immobilisation of the body (i.e., pressure ulcers, pulmonary infections, deep vein thrombosis with pulmonary embolism) and sphincter deficits (urinary tract infections). Urinary tract and bowel dysfunction are common and have a significant impact on the quality of life. Spasticity appears over time. Although it may be painful and result in incapacitating muscle spasms (and should thus be treated either orally or by implantation of an intrathecal drug-delivering pump), spasticity may be beneficial by providing useful some degree of muscle tone for mobilisation. Chronic pain may develop, possibly due to plastic alterations in the sublesional cord circuits, and treatment is difficult. In the presence of neurological deterioration, it is important to search for a cause, since it can be due to the appearance of-or aggravation of syringomyelia. More than half of SCI patients develop heterotopic ossification; in symptomatic cases, treatment is initially conservative (physiotherapy and anti-inflammatory drugs) but can be surgical (resection). In addition, patients are more easily subject to bone fractures in the unused limbs because of osteoporosis due tu underuse. Orthostatic hypertension occurs but tends to resolve over time. SCI above the mid-thoracic cord may result in autonomic dysreflexia with headache, sweating and blood pressure fluctuations, in response to noxious stimuli such as bladder distention and fecal impaction (giving important clinical cues). Maintaining sufficient fluid intake, maximal exercise including neurological rehabilitation, and attentiveness to unusual manifestations (due to loss of sensation below the injury level) of commons problems like urinary tract infections are mandatory [81] .
Clinical trials
There is an impressive number of clinical trials that have been reviewed in great detail by Tator in 2006 [82] , who also addressed deficiencies in the develop-ment of treatment strategies and trial design. In addition, he considered future perspectives, and an up-dated review was provided two years later by Hawryluk and colleagues [83] . The ''bench to bedside'' translation of even encouraging results is hindered by:
(i) the variety of treatment strategies that are available, the magic bullet not having been found, and the probable necessity of using a combination of strategies in order to obtain clinically significant improvement in recovery, and, (ii) the difficulty to compare treatment strategies due to the wide variability in the extent of recovery, even in patient groups with initially homogeneous neurological deficits.
Recent publications addressing the requirements for publication of the results of clinical treatments of SCI have highlighted these difficulties [84] .
Neuroprotective strategies
Pharmacological interventions
The majority of prospective randomised trials have tested pharmacological neuroprotective strategies. In the series of National Acute Spinal Cord Injury Study (NASCIS) trials in the USA, the steroid anti-inflammatory drug methylprednisolone appeared to have shown some promise as a neuroprotective agent at very high doses [85, 86] . However, the NASCIS studies have been criticised [87] , among other things for the inaccessibility of the data, resulting in a tempering of the initial enthusiasm [88] . Thus, despite positive conclusions of a Cochrane review (notably written by the main author of the NASCIS trials himself [89] ), many clinicians do not consider high dose methylprednisolone to be the gold-standard of care, but rather to be a treatment option [90] . According to a set of 2002 Guidelines for Management of Acute Cervical Spinal Cord Injuries, ''treatment with methylprednisolone for either 24 or 48 hours is recommended as an option in the treatment of patients with acute spinal cord injuries that should be undertaken only with the knowledge that the evidence suggesting harmful sideeffects is more consistent than any suggestion of clinical benefit'' [91] . Nonetheless, methylprednisolone is still often used in clinical practice, ''despite the wellfounded criticisms that have been directed against the [NASCIS] trials, given the devastating impact of SCI and the evidence of a modest, beneficial effect of MP'' [92] . Other substances that have been investigated in the clinic include tirilazad, a (non-glucocorticoid) steroid with more specific anti-oxidant, and potentially fewer glucocorticoid side-effects. It appeared to be neither more efficive, nor better tolerated than methylprednisolone [82] . Another compound which was experimentally promising was the monosialoganglioside compound GM1. However, this drug has, so far, not shown any significant clinical benefit [93] . Thyrotropin-releasing hormone (TSH) demonstrated modest neurological benefit in incompletely injured patients, but this was in a small study in which the authors themselves advised caution in the interpretation of the results [94] . At present, there are five on-going pharmacological neuroprotection trials, assessing methylprednisolone, minocycline, erythropoietin, Riluzole, and HP-184 [47] .
Systemic hypothermia
The use of hypothermia after acute traumatic SCI has raised sustained interest in the research community and recently been re-evaluated retrospectively in humans [95] , providing evidence for the safety of the treatment without proving, at present, a beneficial effect on neurological recovery. A multicentre trial has been designed in order to obtain these data (http:==www. miamiproject.miami.edu=page.aspx?pid¼844, accessed 3=3=2011).
Decompression strategies
Early decompression surgery has long been thought by many to provide some degree of neuroprotection by avoiding secondary SCI due to cord compression, based on consistently published favourable results of decompression in animal studies [96] [97] [98] . Early surgery does not appear to be associated with an increased rate of complications [99] . However, clinical evidence for increased neurological recovery remains, at best, tenuous based on the existing trials [100] [101] [102] [103] [104] .
An additional actively investigated approach is the lowering of intrathecal pressure by removal of cerebrospinal fluid, which is thought to decrease tissue ischemia in the injured spinal cord [105] .
Restorative therapies
Overcoming growth inhibition: ''peripheralisation'' of the CNS Restorative therapies have mainly concentrated on overcoming the inhibitory nature of the lesioned, reactive environment within the spinal cord, in order to make the spinal cord permissive to axonal regeneration. In humans, after completion of a phase I trial, a phase II trial of the anti-NOGO antibody is presently under development [106] . Cethrin (BA-210), an antagonist of Rho GTPase, interferes with pathways associated with the inhibition of axonal regeneration. Despite encouraging results in phase I and the beginning of phase II trials, insufficient funding led to the premature termination of this investigation. However, more recently another pharmaceutical company (BioAxone) has expressed interest in the development of the strategy (http:==www. canparaplegic.org=en=Research_32=items=22.html, accessed 3=3=2011). The potential beneficial effects of the oral drug lithium are also being investigated (http:== clinicaltrials.gov=ct2=results?term¼lithiumþspinalþcord, accessed 3=3=2011 ).
Another approach being actively investigated is to overcome the axongrowth inhibitory influences of the lesioned spinal cord by the transplantation of axon-growth promoting cells to modify the local CNS environment, to make it more permissive to axon regrowth. In the first strategy, autologous macrophages (from the patient) which were ''activated'' in vitro, prior to surgical implantation [107] . In an alternative approach, olfactory ensheathing cells have been transplanted into the spinal cord in order to provide a growth permissive environment. This treatment appears to be safe [108] , and a phase I clinical trial is currently under way:
(http:==clinicaltrials.gov=ct2=show=NCT01231893?term¼olfactoryþensheathingþ cells&rank¼1, accessed 3=3=2011).
Providing CNS components with regenerative potential
Stem cells, obtained from umbilical blood or the bone marrow, have been thoroughly investigated in the preclinical setting [108] , and several trials have recently been completed or are still under way (http:==clinicaltrials.gov=ct2= results?term¼stemþcellþspinalþcordþinjury, accessed 3=3=2011). Some investigations in this area have been criticised for lacking scientific rigour [83, 84, 109, 110] .
Stem cell-based strategies have included the use of embryonic stem cells with the caveat of their potential to form teratomas, or the use of differentiated or non-differentiated neural progenitor cells. For SCI repair strategies, predifferentiation of neural progenitors to defined glial phenotypes (e.g. astroglia) or their manipulation to form populations of committed, cell-type specific progenitors (e.g. for the production of oligodendrocytes) have both demonstrated beneficial effects.
Differentiation of neural progenitors to type I astroglial phenotypes have been demonstrated to promote neuroprotection and axon regeneration with improved locomotor function [111] . The strategy of differentiation of stem cells to generate populations of oligodendrocytes progenitors is targeted towards implantation in the acute stages of injury with the goal of remyelination of demyelinated, spared axons after SCI. Such a strategy, using human embryonic stem cell derived oligodendrocyte progenitors has been demonstrated to promote remyelination of denuded axons and some degree of functional improvement [111] . Apart from ethical considerations in the development of such intervention strategies, a significant challenge for most of these stem-cell based strategies is the allogenic nature of the donor cells, requiring immunosuppression to prevent rejection by the host. In an attempt to obtain more clinically relevant, autologous donor cells, induced pluripotent stem cell (iPSC) technology has been developed. This technology allows the reprogramming of somatic cells to a stem cell-like phenotype, thus avoiding ethical issues [112] . However, the re-programming of cells appears to be a rather inefficient and concerns regarding tumour or teratoma formation persist.
Rehabilitation
In SCI patients, body weight supported treadmill training (BWSTT) and other intensive neurorehabilitative measures have been increasingly used since the first reports of the potential benefits of BWSTT almost two decades ago [49, 113] . Encouraging preliminary clinical and electrophysiological results have been obtained [114] . It has been reported that a single patient, after several years of stability in the absence of nearly all sensori-motor function below the shoulders, recovered some function (evolution from ASIA grades A to grade C) following highly sophisticated and intense rehabilitative measures, including bicycle training and functional electrical stimulation [115] . These potential beneficial effects may, however, be largely limited to incompletely injured patients [116] : in a comparative study of the effect of training on complete and incomplete cord syndromes, improvements in the neurological outcome only occurred in patients with the incomplete SCI syndromes over the training period [50] .
At present, the available clinical evidence for a reproducible and significant positive effect on locomotion still remains somewhat tenuous, because of the heterogeneity of the clinical presentation, the limited range of beneficial effects, the possibility for spontaneous beneficial evolution, the limited number of patients, and the lack of randomised studies. Even if overground training in the setting of subacute incomplete motor spinal cord injury results in increased independent walking, more randomized controlled trials will be needed to clarify the effectiveness of sophisticated, SCI-specific rehabilitation techniques such as body weight-supported gait training and robotic training. Such trials must include beneficial effects on locomotion as well as on activities required for ''normal'' daily living, and the quality of life [117, 118] .
Conclusion
SCI remains a challenge for the clinician and the scientist. Treatment strategies are steadily evolving, though, and major advances in the understanding of the pathophysiological mechanisms of SCI open promising new therapeutic perspectives. Even if complete recovery remains at present an elusive goal, due the complexity of the task to repair the spinal cord and retrain its neural circuitry, a strategy which combines several of the different approaches described above may result in some degree of useful neurological improvement for spinal cord injured patients.
The conceptual framework for the combination of treatment strategies includes initial neuroprotection in order to minimise secondary progression of the injury, followed by the enhancement of CNS regeneration, including the implantation of a three dimensional scaffold as an axon growth promoting bridge to reconnect the disconnected neuronal circuits, and, finally, retraining and enhancing plasticity of the preserved (and hopefully re-built) parenchyma.
Even if the significant research efforts presently under way may lead to only moderate functional results, two aspects of this complex issue must be taken into account in order to put this into perspective. First, the anatomical reconstruction of the spinal cord and its three dimensional architecture does not have to be ''complete'' for enhancing recovery; the reestablishment of a minority of long tracts may suffice to obtain major neurological recovery. Second, even small increments in function may have much more significant effects on patient health and autonomy than their pure ''neurological magnitude''. For example, a slight increase in lower limb motor function may make the difference between a completely dependent bed-ridden patient and a patient who can stand with crutches, or between a patient who can only stand and a patient who will be able to make a few steps and move independently without a wheelchair. Preservation of one spinal segment in the low cervical spine may result in useful function of the distal upper limb muscles, i.e., those of the hand, coordinating finger movements. A slight increase in sphincter function may increase the duration a patient can spend away from the facilities he=she had become dependent upon and decrease the number of urinary tract infections.
In order to maximise potential treatment effects, it is crucial to structure research efforts efficiently. Experimentally well-confirmed treatment strategies (and their combinations) must be carefully brought from the bench to the bedside, and their introduction into clinical research must be guided by scientific rigour. This must take into account the necessity to recruit high numbers of subjects from a relatively small patient population. If research efforts are coordinated and joined rationally, we may witness, within the coming decades, the achievement of reproducible neurological treatment effects and, hopefully, significant improvements in the quality of life of SCI patients.
In the meantime, prevention of the injury remains the most efficient strategy, and the implementation of preventive strategies must be the focus of public health efforts in the area of SCI. Among those strategies that have been reliably evaluated in humans, all patients should be offered multidisciplinary rehabilitation, as intensely as feasible in given local settings.
